3D Systems Corp: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 26, 2024 and accepted by EDGAR at Nov 26, 2024, 17:12 ET.
Management's discussion and analysis
As filed, 115,562 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q (the “Financial Statements”). Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that may affect our future performance that are discussed in greater detail under the headings “Forward Looking Statements” below; in Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q; and in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”).
Business Overview
3D Systems Corporation (“3D Systems,” the “Company,” “we,” “our,” or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions and Industrial Solutions. We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.
The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve their overall total cost of operation. Our technologies and process knowledge enable over a million production parts to be made through additive manufacturing each day.
Recent Developments and Updates Regarding Strategic Initiatives
Ongoing Fiscal Year 2023 Restructuring Plan
Restructuring Plan Objectives and Status of Execution
In 2023, the Company commenced a multi-faceted restructuring plan (the “2023 Restructuring Plan”) to improve operating efficiencies throughout the organization and drive long-term value creation. The key initiatives of the plan, some of which are ongoing, were announced in 2023 and included:
- improving manufacturing efficiencies related to the Company’s European metal printer operations by (1) in-sourcing certain metal printer platforms into the Company’s Riom, France manufacturing facility and (2) co-locating the engineering and manufacturing of in-sourced metal printer products in order to improve cycle time from development to production;
- reducing headcount throughout all functions and areas of the organization; and
- rationalizing the Company's geographic footprint through the exit of leased facilities.
As of September 30, 2024, the Company has substantially completed its in-sourcing activities. Actions taken to reduce headcount commenced during the year ended December 31, 2023 and were substantially completed during the three months ended September 30, 2024.
During the last quarter of our fiscal year ended December 31, 2023, the Company began identifying and evaluating opportunities to exit leased facilities as part of its efforts to rationalize its geographic footprint. Throughout the nine month period ended September 30, 2024, the Company (1) has partially or fully exited 15 leased facilities that were identified as part of the Company's plan and (2) has commenced active marketing efforts to sublease facilities that have been fully exited. The Company expects to have exited all facilities identified as part of its facilities rationalization plan by December 31, 2024.
2023 Restructuring Plan Costs, Cash Settlements and Recognized Liabilities
Headcount Reductions
We incurred a total of $8.6 million in severance and termination benefit costs related to headcount reductions between inception of our 2023 Restructuring Plan and the substantial completion of headcount reductions under the plan during the three months ended September 30, 2024. These costs were generally recognized when probable and estimable because they were typically determined consistent with the Company’s past practices or statutory law.
The severance, termination benefit and other employee costs that were incurred under our 2023 Restructuring Plan during the nine months ended September 30, 2024 and 2023, as well as the related accrued liability balance as of each respective balance sheet date, are as follows:
(in thousands)
| September 30, 2024 | September 30, 2023 | |
|---|---|---|
| Balance at beginning of period | $3,933 | $— |
| Costs incurred during the period | 318 | 3,724 |
| Amounts settled with cash | (2,909) | (2,693) |
| Balance at the end of period | $1,342 | $1,031 |
Facilities Rationalization
Since inception of the 2023 Restructuring Plan, we have incurred $0.5 million in lease termination costs and, during 2023, we recorded $0.6 million in incremental impairment charges related to certain fixed assets that have been retired in connection with the Company’s restructuring. Our condensed consolidated financial statements have not reflected additional material charges resulting from decisions to exit facilities because either (1) the Company has not ceased use of a facility that it plans to exit or (2) an individual facility (and any related assets, as applicable) do not yet qualify to be measured for impairment separate from the asset group to which it has historically belonged, which would generally occur when we have entered into a sublease. As we continue to exit the remaining facilities identified as part of our facilities rationalization plan, we expect to incur cash expenditures (costs) related to relocation activities, which amounts will be expensed as incurred. We also may incur non-cash impairment charges, incremental to those resulting from our impairment testing described in Note 8 to the Financial Statements, if the carrying values of right-of-use asset balances related to exited facilities and other related asset balances (e.g., leasehold improvements) will not be fully recoverable through our efforts to sublease an exited facility. We currently expect aggregate annualized cost savings from our 2023 Restructuring Plan to be between $45.0 and $55.0 million when completed.
Other Strategic Business Decisions and Cost Saving Initiatives
Oqton
Throughout the nine months ended September 30, 2024, the Company continued to evaluate strategic alternatives related to Oqton, Inc. ("Oqton") MOS, for which the Company previously disclosed during the year ended December 31, 2023 that it is more likely than not the business would be sold or otherwise disposed of. In connection with the expectation to sell or otherwise dispose of Oqton MOS, management previously assessed whether the carrying value of this asset group’s long-lived assets was recoverable, which resulted in a full impairment of the asset group's intangible assets during the year ended December 31, 2023. As a result of the impairment of Oqton MOS’s intangible assets during the year ended December 31, 2023, the Company has recognized lower amortization expense attributable to intangible assets for the three and nine months ended September 30, 2024, as compared to the three and nine months ended September 30, 2023. No incremental impairment charges have been recognized with respect to the carrying values of the asset group's other assets during the three or nine months ended September 30, 2024.
During May 2024, the Company completed the sale of the portion of the Oqton MOS business that was focused on the dental market ("Oqton Dental") in exchange for a de minimis amount of cash, resulting in the transfer of a limited portion of Oqton MOS's personnel and a de minimis amount of fixed assets. The sale of Oqton Dental does not qualify as a discontinued operation, as it does not represent a strategic shift that will have a major effect on our overall business operations; however, the transfer of personnel is expected to provide cost savings from the date of the disposal of Oqton Dental. The Company continues to evaluate strategic alternatives related to the remaining portion of Oqton MOS that the Company continues to hold.
Investing in Regenerative Medicine
Within our Healthcare Solutions segment, a portion of our business focuses on opportunities for additive manufacturing to be applied to regenerative medicine. To date, our efforts in the area of regenerative medicine have consisted primarily of pre-commercial bio-technology research and development (“R&D”) in the areas described below.
Our first area of focus is the use of additive manufacturing for human organ transplantation, with a long-term goal of helping patients with end-stage disease receive transplants that will enable them to enjoy long and active lives. This program combines our 3D printing expertise and capabilities in human tissue engineering with the regenerative medicine and biotechnology expertise of a key strategic partner. Through the start of 2024, our program focused on developing the capability to print organ scaffolds for human lungs, kidneys and livers. However, beginning in the first quarter of 2024, due to changes to our arrangement with and funding from our key strategic partner, the Company’s continuing organ program shifted its focus to developing the capability to print human lung scaffolds, for which the related R&D efforts will continue to be primarily funded by our key strategic partner. Refer to Note 12 and Note 17 to the Financial Statements for additional information regarding the impact of the changes to this program.
Our second area of focus seeks to utilize our bio-printing capabilities to design and manufacture 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers through our wholly-owned biotech company, Systemic Bio. We believe that “organs-on-chips” can accelerate the drug development process and reduce the cost of pre-clinical drug testing, as well as reduce the pharmaceutical industry’s reliance on animal testing. Systemic Bio combines 3D Systems’ legacy expertise in high-resolution 3D printing with advanced capabilities in bioprinting and biomaterials to design and market 3D-printed, vascularized “organs-on-chips”. During the year ended December 31, 2023, Systemic Bio entered into its first commercial contracts with pharmaceutical industry customers.
Acquisitions/Investments
Incremental Investment in National Additive Manufacturing Innovation (“NAMI”) Joint Venture
In May 2024, the Company made an incremental investment of $2.5 million in NAMI, the Company's joint venture with Dussur. Refer to Note 7 to the Financial Statements for additional details regarding this equity method investment.
Acquisition of Wematter
On July 1, 2023, the Company completed the acquisition of Wematter AB (“Wematter”), a Swedish 3D printer manufacturer, for which post-acquisition results are included in our Industrial Solutions segment. The acquisition broadens 3D Systems’ Selective Laser Sintering (SLS) portfolio. Consideration for this acquisition consisted of approximately $10.2 million in cash, subject to customary post-closing adjustments. The Company also may be required to pay an additional €2.0 million in cash, contingent upon the achievement of certain post-closing performance conditions and the continued employment of certain key employees of Wematter for two years after the closing date of the acquisition. As of September 30, 2024, management does not believe that achievement of the post-closing performance conditions is probable. Refer to Note 2 to the Financial Statements for additional details regarding this acquisition.
Background
We earn revenue from the sale of products and services through our Healthcare Solutions and Industrial Solutions segments. The product categories include 3D printers and corresponding materials, digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services categories include maintenance contracts and services on 3D printers, software maintenance, software as a service subscriptions and healthcare solutions services.
Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.
In addition to changes in sales volumes, there are two other primary drivers of changes in revenue from one period to another: (1) the combined effect of changes in product mix and average selling prices and (2) the impact of fluctuations in foreign currencies. As used in this MD&A, the price and mix effects relate to changes in revenue that are not able to be specifically attributed to changes in unit volume or changes in foreign exchange rates.
How We Assess the Performance of Our Business
We manage operations through the two business segments described above. In addition to our consolidated GAAP financial measures, we review Adjusted EBITDA.
We believe Adjusted EBITDA is a helpful supplemental measure to assist us and investors in evaluating our operating results, as Adjusted EBITDA excludes certain items for which the fluctuation from period to period does not necessarily correspond to changes in the operations of our business. Adjusted EBITDA represents net income (loss), plus income tax (provision) benefit, interest and other income (expense), net, stock-based compensation expense, amortization of intangible assets, depreciation expense, and certain other non-GAAP adjustments. We believe that the adjustments applied in presenting Adjusted EBITDA are appropriate to provide additional information to investors about our operating and financial performance without (1) the effect of certain material non-cash items and (2) certain items that we do not believe to be core to our operations.
Management and our Board of Directors regularly use Adjusted EBITDA in evaluating our operating and financial performance and in establishing discretionary annual compensation. This measure is provided in addition to, and should not be considered to be a substitute for, or superior to, comparable measures determined in accordance with GAAP. In addition, we believe that Adjusted EBITDA is frequently used by investors and other interested parties in the evaluation of other issuers, many of which also present Adjusted EBITDA when reporting their results in an effort to augment investors' understanding of their operating and financial results; however, similarly titled measures provided by other issuers may not be calculated in the same manner and/or using the same adjustments.
Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other performance measure derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP.
For further information regarding Adjusted EBITDA, see “Non-GAAP Earnings” below.
Consolidated Financial Results for the Three and Nine Months Ended September 30, 2024 and 2023
(in thousands)
| Revenue: | Three Months Ended September 30, 2024 | September 30, 2023 | Nine Months Ended September 30, 2024 | September 30, 2023 |
|---|---|---|---|---|
| Products | $72,968 | $80,415 | $208,752 | $253,968 |
| Services | 39,972 | 43,376 | 120,345 | 119,253 |
| Total revenue | 112,940 | 123,791 | 329,097 | 373,221 |
| Cost of sales: | ||||
| Products | 47,533 | 47,427 | 129,571 | 153,442 |
| Services | 23,694 | 21,014 | 69,793 | 67,315 |
| Total cost of sales | 71,227 | 68,441 | 199,364 | 220,757 |
| Gross profit | 41,713 | 55,350 | 129,733 | 152,464 |
| Operating expenses: | ||||
| Selling, general and administrative | 57,974 | 33,355 | 166,772 | 150,623 |
| Research and development | 20,764 | 21,982 | 66,260 | 66,953 |
| Asset impairment charges | 143,733 | 13,597 | 143,733 | 13,597 |
| Total operating expenses | 222,471 | 68,934 | 376,765 | 231,173 |
| Loss from operations | (180,758) | (13,584) | (247,032) | (78,709) |
| Non-operating income (expense): | ||||
| Foreign exchange (loss) gain, net | (1,960) | (2,202) | (774) | (3,847) |
| Interest income | 1,550 | 5,841 | 5,800 | 15,730 |
| Interest expense | (606) | (932) | (1,944) | (2,612) |
| Other (expense) income, net | (51) | (105) | 21,719 | 420 |
| Total non-operating (loss) income | (1,067) | 2,602 | 24,801 | 9,691 |
| Loss before income taxes | (181,825) | (10,982) | (222,231) | (69,018) |
| Benefit (provision) for income taxes | 4,343 | (174) | 2,496 | (404) |
| Loss on equity method investment, net of income taxes | (1,254) | (605) | (2,403) | (747) |
| Net loss before redeemable non-controlling interest | (178,736) | (11,761) | (222,138) | (70,169) |
| Less: net loss attributable to redeemable non-controlling interest | (109) | (57) | (252) | (149) |
| Net loss attributable to 3D Systems Corporation | $(178,627) | $(11,704) | $(221,886) | $(70,020) |
| Other Financial Data: | ||||
| Adjusted EBITDA | $(14,342) | $4,726 | $(47,312) | $(12,266) |
36
Consolidated Operating Results for the Three Months Ended September 30, 2024 Compared to the Three Months Ended September 30, 2023
Consolidated revenue
The following table sets forth changes in our products and services revenue for the three months ended September 30, 2024 and 2023.
(Dollars in thousands)
| Products | Services | Total | ||||
|---|---|---|---|---|---|---|
| Revenue — three months ended September 30, 2023 | $80,415 | 65.0% | $43,376 | 35.0% | $123,791 | 100.0% |
| Change in revenue: | ||||||
| Volume | 2,211 | 2.7% | (3,483) | (8.0)% | (1,272) | (1.0)% |
| Price/mix | (10,129) | (12.6)% | — | —% | (10,129) | (8.2)% |
| Foreign currency translation | 471 | 0.6% | 79 | 0.2% | 550 | 0.4% |
| Net change | (7,447) | (9.3)% | (3,404) | (7.8)% | (10,851) | (8.8)% |
| Revenue — three months ended September 30, 2024 | $72,968 | 64.6% | $39,972 | 35.4% | $112,940 | 100.0% |
Products revenue
For the three months ended September 30, 2024, products revenue decreased by $7.4 million, or 9.3%, as compared to the three months ended September 30, 2023. This decrease is primarily attributable to a $10.1 million, or 12.6%, negative impact of changes in price/mix. The unfavorable impact of changes in price/mix is primarily attributable to the significant increase in the volume of materials sales to our key customer in the dental industry (see discussion below) at lower pricing as compared to the three months ended September 30, 2023 and lower pricing of certain materials sold by our Industrial Solutions segment.
The negative impact of changes in price/mix on product revenue reported for the three months ended September 30, 2024 was partially offset by a $2.2 million, or 2.7%, positive impact of higher sales volume. This $2.2 million increase in products revenue due to higher sales volume reflects a $12.0 million increase in revenue attributable to a higher volume of materials sales, offset by a $9.8 million decrease in revenue attributable to a lower volume of printer and products sales. The increase in material sales volume for the three months ended September 30, 2024 is primarily attributable to a significant increase in the volume of materials sold to our key customer in the dental industry, to which materials sales returned to normalized levels for the three months ended September 30, 2024. During the three months ended September 30, 2023, we experienced a lower volume of materials sales to our key customer in the dental industry due to the customer's higher inventory on hand during the period.
Printer sales volume decreased for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the general impact of macroeconomic conditions on printer sales across our business given the capital expenditure nature of such customer purchases. Due to the high price of certain 3D printers, our total products revenue can be materially impacted by period-over-period changes in the concentration of printer orders and shipments. Further contributing to our lower printer revenue due to lower sales volumes during the three months ended September 30, 2024, was a decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024.
Services revenue
For the three months ended September 30, 2024, services revenue decreased by $3.4 million, or 7.8%, as compared to the three months ended September 30, 2023. Contributing to this decrease in services revenue was a $4.5 million revenue catch-up adjustment recognized during the three months ended September 30, 2023, which related to variable consideration included in a collaboration and licensing agreement. As a result of an amendment to the collaboration and licensing agreement during the three months ended September 30, 2023, the Company concluded that three additional milestone-based payments included in the contract, totaling $6.5 million in the aggregate, became probable of being earned. This resulted in the recognition of the $4.5 million revenue catch-up adjustment during the three months ended September 30, 2023, as no revenue had previously been recognized related to the three additional milestone payments. No similar adjustments were recorded to recognize incremental contract revenue during the three months ended September 30, 2024.
Further contributing to the $3.4 million decrease in services revenue was the impact of macroeconomic conditions on services sales by our Industrial Solutions segment, partially offset by higher personalized health services revenue and higher services sales to our key dental customer.
Total revenue
For the three months ended September 30, 2024, revenue decreased by $10.9 million, or 8.8%, as compared to the three months ended September 30, 2023. This decrease was primarily driven by the $7.4 million decrease in our products revenue and the $3.4 million decrease in our services revenue. Refer to the discussions of products revenue and services revenue above for additional details.
Consolidated gross profit
(Dollars in thousands)
| Three Months Ended September 30, 2024 Gross Profit | Gross Profit Margin | September 30, 2023 Gross Profit | Gross Profit Margin | Change in Gross Profit $% | Change in Gross Profit Margin Percentage Points% | |||
|---|---|---|---|---|---|---|---|---|
| Products | $25,435 | 34.9% | 32,988 | 41.0% | $(7,553) | (22.9)% | (6.1) | (14.9)% |
| Services | 16,278 | 40.7% | 22,362 | 51.6% | (6,084) | (27.2)% | (10.9) | (21.1)% |
| Total | $41,713 | 36.9% | $55,350 | 44.7% | $(13,637) | (24.6)% | (7.8) | (17.4)% |
Consolidated gross profit and gross profit margin
Our consolidated gross profit for the three months ended September 30, 2024 decreased $13.6 million, or 24.6%, to $41.7 million, as compared to $55.4 million for the three months ended September 30, 2023. Our consolidated gross profit margin decreased to 36.9% for the three months ended September 30, 2024, as compared to 44.7% for the three months ended September 30, 2023.
Our consolidated gross profit was negatively impacted by the $10.9 million, or 8.8%, decrease in our consolidated revenue for the three months ended September 30, 2024. This decrease in our consolidated revenue reflected decreases in both products revenue and services revenue that resulted in decreases in both products gross profit and services gross profit, respectively. Further contributing to the decrease in our consolidated gross profit is the 780 basis point decrease in our consolidated gross profit margin for the three months ended September 30, 2024, reflecting significant decreases in the gross profit margins realized on both products revenue and services revenue.
Refer to the discussions below for details regarding the factors that have impacted products and services gross profit and products and services gross profit margins for the three months ended September 30, 2024.
Products gross profit and gross profit margin
For the three months ended September 30, 2024, gross profit from products sales decreased by $7.6 million, or 22.9%, as compared to the three months ended September 30, 2023. This decrease in gross profit recognized from products sales is due to the $7.4 million, or 9.3%, decrease in products revenue for the three months ended September 30, 2024, as well as the 610 basis point decrease in gross profit margin realized on products revenue. The most significant contributors to the decrease in our products gross profit margin for the three months ended September 30, 2024 were (1) a $2.7 million increase in the provision recorded for inventory obsolescence during the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, and (2) unfavorable manufacturing variances.
Services gross profit and gross profit margin
For the three months ended September 30, 2024, gross profit from services sales decreased by $6.1 million, or 27.2%, as compared to the three months ended September 30, 2023. This decrease in gross profit recognized on services revenue is due to the $3.4 million, or 7.8%, decrease in services revenue for the three months ended September 30, 2024, as well as the 1,090 basis point decrease in the gross profit margin realized on services revenue for the period. Contributing to the higher services revenue and higher gross profit and gross profit margin realized on services revenue for the three months ended September 30, 2023 was $4.5 million of incremental variable consideration revenue recognized by the Company's Healthcare Solutions segment during the three months ended September 30, 2023 upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement were probable of being earned. As there were no direct costs (e.g., costs of goods sold) associated with this incremental collaboration and licensing revenue, the entire $4.5 million contributed to an increase in reported gross profit and gross profit margin realized on services revenue for the three months ended September 30, 2023. The Company did not recognize a similar catch-up adjustment to services revenue during the three months ended September 30, 2024.
Consolidated selling, general and administrative expense
Selling, general and administrative ("SG&A") expense for the three months ended September 30, 2024 increased $24.6 million, or 73.8%, to $58.0 million, as compared to $33.4 million for the three months ended September 30, 2023. The primary drivers of the $24.6 million increase in SG&A expense reported for the three months ended September 30, 2024 are as follows:
| Primary drivers (in thousands) | Increase / (Decrease) |
|---|---|
| Volumetric earnout | $20,280 |
| Amortization expense | 4,942 |
| Audit, legal and third-party consulting costs | 731 |
| Compensation and benefits | (1,271) |
| Other | (63) |
| Total change | $24,619 |
39
Volumetric earnout
SG&A expense increased $20.3 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, as the Company recognized the reversal of $20.3 million of Volumetric earnout expense during the three months ended September 30, 2023, as compared to recognizing no Volumetric earnout expense during the three months ended September 30, 2024. Prior to the quarter ended September 30, 2023, the Company had been accruing for a $65 million earnout payment (compensation expense) because the Company had concluded that a non-financial, scientific milestone included in the acquisition agreement related to the Company's December 2021 acquisition of Volumetric was probable of achievement. However, during the three months ended September 30, 2023, the Company concluded that this non-financial, scientific milestone was no longer probable of achievement given a reduction in the budgeted funding for the related R&D efforts. Accordingly, the Company reversed all previously recognized earnout expense related to the non-financial, scientific milestone during the three months ended September 30, 2023, and has recognized no earnout expense related to this non-financial, scientific milestone in reporting periods occurring thereafter. Furthermore, as a result of events that have occurred during the nine months ended September 30, 2024, the Company has notified the sellers of Volumetric that they are no longer eligible to earn any of the milestone-based earnout payments contemplated in the Volumetric acquisition agreement. Refer to the discussions in Note 12 and Note 17 to the Financial Statements, for additional details regarding the Company's cancellations of the Volumetric sellers' rights to future earnout payments, as well as actions taken in response to these cancellations.
Amortization expense
Amortization expense increased by $4.9 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. This increase in amortization expense was primarily due to a reduction in the estimated remaining useful lives of certain intangible assets, resulting in the recognition of higher amortization expense during the three months ended September 30, 2024. Partially offsetting the impact of the reduced useful lives for certain intangible assets is lower amortization expense resulting from impairment charges that reduced the carrying values of intangible assets included in both the Oqton MOS asset group (refer to Note 5) and the dp polar asset group to $0 during the three months ended September 30, 2023 and December 31, 2023, respectively. Refer to the discussion of "Other Strategic Business Decisions and Cost Saving Initiatives" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's recent actions taken with respect Oqton.
Audit, legal and third-party consulting costs
Audit, legal and third-party consulting costs increased $0.7 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, primarily due to the continued recognition of costs to complete our fiscal year 2023 audit, including costs paid to our former independent registered public accounting firm and third-party accounting and finance consulting support costs; whereas, our fiscal year 2022 audit was completed prior to the three months ended September 30, 2023. The increases in audit and third-party consulting costs were partially offset by lower acquisition-related legal costs as compared to the three months ended September 30, 2023 when the Company's was pursuing a large acquisition.
Compensation and benefits
Compensation and benefits expense decreased by $1.3 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. This decrease was primarily driven by a $3.3 million decrease in stock-based compensation expense (excluding the impact of the reversal of the portion of the Volumetric earnout expense discussed above that was subject to settlement in shares of Common Stock) and a $0.7 million decrease in severance expense, partially offset by a $2.9 million increase in bonus compensation expense. The decrease in stock-based compensation expense for the three months ended September 30, 2024 is primarily due to (1) the reversal of $2.1 million of expense previously recognized under the Company's Systemic Bio Phantom Unit Plan, as compared to the recognition of $0.2 million of expense under this stock-based compensation plan during the three months ended September 30, 2023, and (2) the delayed grant of fiscal year 2024 annual share-based payment awards under the Company's 2015 Incentive Plan until September and October of 2024, as compared to fiscal year 2023 annual share-based payment award grants occurring in April of 2023. Refer to Note 12 to the Financial Statements for additional details regarding the reversal of stock-based compensation recognized under the Company's Systemic Bio Phantom Unit Plan.
Cash bonus expense for the three months ended September 30, 2024 and 2023 reflects the amount of cash bonus compensation required to be recognized to appropriately report the Company's bonus liability as of each respective balance sheet date. The liability reported as of each balance sheet date is based upon management's estimate of annualized bonus expense, after consideration of the Company's performance relative to annual performance targets established under the bonus plan. For the three months ended September 30, 2024, the Company recorded incremental bonus expense based upon management's estimate of the fiscal year 2024 annual bonus expense; whereas, the Company reversed substantially all of the previously accrued fiscal year 2023 bonus expense during the three months ended September 30, 2023.
The decrease in severance expense recognized for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, is due to the recognition of higher severance and termination benefit charges that were recorded to SG&A expense during the prior year period in connection with our 2023 Restructuring Plan. Under our 2023 Restructuring Plan, employee severance and termination benefit costs generally have been recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law. Furthermore, the classification of these severance and termination benefit costs in our statement of operations is based upon the classification of the ordinary compensation expense attributable to the impacted employees.
Consolidated research and development expense
R&D expense for the three months ended September 30, 2024 decreased $1.2 million, or 5.5%, to $20.8 million, as compared to $22.0 million for the three months ended September 30, 2023. Lower R&D expense was primarily driven by cost savings realized under the Company's 2023 Restructuring Plan, as well as a decrease in costs due to the sale of Oqton Dental. Refer to the discussion in the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding these activities.
Asset impairment charges
During the three months ended September 30, 2024 and 2023, we recorded asset impairment charges of $143,733 and $13,597, respectively. The following table summarizes the nature of the assets for which impairment charges were recorded during the three months ended September 30, 2024 and 2023:
(in thousands)
| Three Months Ended September 30, 2024 | 2023 | |
|---|---|---|
| Goodwill | $101,445 | $— |
| Intangible assets | 31,198 | 13,597 |
| Property and equipment | 5,911 | — |
| Right-of-use assets | 5,179 | — |
| Total asset impairment charges | $143,733 | $13,597 |
41
Impairments during the three months ended September 30, 2024
As a result of the significant decline in the trading price of our Common Stock and our market capitalization during the three months ended September 30, 2024, as well as reduced long-term cash flow forecasts prepared in connection with the Company's recently commenced long-range planning process, the Company concluded that the performance of an interim period goodwill impairment test was required as of September 30, 2024. For purposes of this goodwill impairment test, all of our goodwill was allocated to our Healthcare Solutions reportable segment, which also represents the reporting unit to which the goodwill is assigned for testing purposes. The performance of the interim period goodwill impairment test required the Company to compare the carrying value of the Healthcare Solutions reporting unit to its fair value estimated as of September 30, 2024. The carrying value of this reporting unit was estimated to exceed its fair value by $101.4 million, resulting in the recognition of a goodwill impairment charge equal to such amount for the three months ended September 30, 2024. Refer to Note 6 to the Financial Statements for additional details regarding the goodwill impairment charge.
During the three months ended September 30, 2024, the Company concluded that the reduced long-term cash flow forecasts prepared in connection with the Company's recently commenced long-range planning process, combined with the Company's reported losses and negative cash flows for both current and historical reporting periods, were indicators that the primary asset group underlying the Company's core operations should be tested for recoverability. As discussed in Note 1, Note 5 and Note 8 the Company determined that the carrying value of its primary asset group exceeded its fair value. This resulted in the recognition of impairment charges of $31.2 million, $5.9 million and $5.2 million related to intangible assets, property and equipment, and right-of-use assets, respectively, during the three months ended September 30, 2024.
Impairments during the three months ended September 30, 2023
During the quarter ended September 30, 2023, the Company concluded that it was more likely than not that it would sell or otherwise dispose of Oqton MOS, a business which the Company acquired in 2021. Based upon the Company's expectation to sell or otherwise dispose of Oqton MOS, the Company assessed the carrying value of Oqton MOS's long-lived assets, a discrete asset group consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, for both recoverability and impairment. The Company's assessment resulted in the recognition of impairment charges totaling $13.6 million related to the acquired technology and trade names included in the Oqton MOS asset group during the three months ended September 30, 2023. Refer to Note 5 to the Financial Statements for additional details.
Consolidated operating loss
Our operating loss for the three months ended September 30, 2024 was $180.8 million, as compared to a $13.6 million operating loss for the three months ended September 30, 2023. Our reported operating loss for the three months ended September 30, 2024 increased due to (1) the significant increase in the asset impairment charges recognized; (2) the significant increase in SG&A costs, which includes the impact of reversing the Volumetric earnout expense liability during the three months ended September 30, 2023, as there was not a comparable significant reversal of an expense or liability during the three months ended September 30, 2024; and (3) the decrease in our gross profit realized for the three months ended September 30, 2024 due to lower reported products and services revenues and lower realized products and services gross profit margins. Refer to the revenue, gross profit and cost discussions above for additional details.
Consolidated Operating Results for the Nine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023
The following table sets forth changes in our products and services revenue for the nine months ended September 30, 2024 and 2023.
(Dollars in thousands)
| Products | Services | Total | ||||
|---|---|---|---|---|---|---|
| Revenue — nine months ended September 30, 2023 | $253,968 | 68.0% | $119,253 | 32.0% | $373,221 | 100.0% |
| Change in revenue: | ||||||
| Volume | (31,192) | (12.3)% | 1,287 | 1.1% | (29,905) | (8.0)% |
| Price/mix | (13,726) | (5.4)% | 1 | —% | (13,725) | (3.7)% |
| Foreign currency translation | (298) | (0.1)% | (196) | (0.2)% | (494) | (0.1)% |
| Net change | (45,216) | (17.8)% | 1,092 | 0.9% | (44,124) | (11.8)% |
| Revenue — nine months ended September 30, 2024 | $208,752 | 63.4% | $120,345 | 36.6% | $329,097 | 100.0% |
Products revenue
For the nine months ended September 30, 2024, products revenue decreased by $45.2 million, or 17.8%, as compared to the nine months ended September 30, 2023. This decrease is attributable to both a significant decline in sales volume and a significant unfavorable impact of price/mix. The $31.2 million, or 12.3%, decrease in products revenue due to lower sales volume reflects a $47.8 million decrease in revenue that is primarily attributable to a lower volume of printer and other products sales, partially offset by a $16.6 million increase in revenue attributable to a higher volume of materials sales. Printer sales volume decreased for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 due to (1) a significant decline in printer sales to our key customer in the dental industry, to which we also expect limited printer sales for the remainder of 2024, and (2) the general impact of macroeconomic conditions on printer sales more broadly across our business due to the capital expenditure nature of such customer purchases. Due to the high price of certain 3D printers, our total products revenue can be materially impacted by period-over-period changes in the concentration of printer orders and shipments.
In addition, printer and products revenue decreased $6.4 million due to the loss of revenue attributable to our regenerative medicine kidney and liver R&D program, as well as lower revenue recognized related to our regenerative medicine lung R&D program due to less R&D activity performed during the nine months ended September 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the change to our organs R&D program that resulted in the loss of revenue attributable to kidney and liver research.
The decrease in products revenue attributable to the lower volume of printer sales and the decrease in R&D activity performed under our regenerative medicine organ program was partially offset by a $16.6 million increase in revenue attributable to a higher volume of materials sales. This increase in volume was primarily driven by increased materials sales to our key customer in the dental industry, which returned to normalized levels for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, we experienced significantly lower materials sales to this key customer due to the customer's higher inventory on hand during the period. The higher volume of materials sales to our key customer in the dental industry was partially offset by lower materials sales volume elsewhere in our business, largely driven by slower sell through of materials inventory at certain customers.
Products revenue for the nine months ended September 30, 2024 decreased $13.7 million due to changes in price/mix, which primarily reflects an unfavorable impact of the increased volume of materials sales to our key customer in the dental industry at lower pricing as compared to the nine months ended September 30, 2023. As materials sales volume decreased elsewhere in our business, materials sales to this key customer in the dental industry also represented a higher percentage of our total materials sales.
Services revenue
For the nine months ended September 30, 2024, services revenue increased by $1.1 million, or 0.9%, as compared to the nine months ended September 30, 2023. This increase was primarily driven by increases in personalized healthcare services revenue, an increase in parts and maintenance revenue related to the installed printer base at our key dental industry customer, and revenue generated from a significant Industrial Solutions services contract.
Total revenue
For the nine months ended September 30, 2024, revenue decreased by $44.1 million, or 11.8%, as compared to the nine months ended September 30, 2023. This decrease was primarily driven by the $45.2 million decrease in our products revenue, which was only partially offset by a $1.1 million increase in our services revenue. Refer to the discussions of products revenue and services revenue above for additional details.
Consolidated gross profit
(Dollars in thousands)
| Nine Months Ended September 30, 2024 Gross Profit | Gross Profit Margin | September 30, 2023 Gross Profit | Gross Profit Margin | Change in Gross Profit $% | Change in Gross Profit Margin Percentage Points% | |||
|---|---|---|---|---|---|---|---|---|
| Products | $79,181 | 37.9% | 100,526 | 39.6% | $(21,345) | (21.2)% | (1.7) | (4.3)% |
| Services | 50,552 | 42.0% | 51,938 | 43.6% | (1,386) | (2.7)% | (1.6) | (3.7)% |
| Total | $129,733 | 39.4% | $152,464 | 40.9% | $(22,731) | (14.9)% | (1.5) | (3.7)% |
Consolidated gross profit and gross profit margin
Our consolidated gross profit for the nine months ended September 30, 2024 decreased $22.7 million, or 14.9%, to $129.7 million, as compared to $152.5 million for the nine months ended September 30, 2023. Our consolidated gross profit margin decreased to 39.4% for the nine months ended September 30, 2024, as compared to 40.9% for the nine months ended September 30, 2023.
Our consolidated gross profit was negatively impacted by the $44.1 million, or 11.8%, decrease in our consolidated revenue for the nine months ended September 30, 2024, as well as the lower gross profit margins realized on both products revenue and services revenue. Refer to the discussions below for additional details regarding the factors that have impacted products and services gross profit and products and services gross profit margins for the nine months ended September 30, 2024.
Products gross profit and gross profit margin
For the nine months ended September 30, 2024, gross profit from products sales decreased by $21.3 million, or 21.2%, as compared to the nine months ended September 30, 2023. This decrease in gross profit from products sales is primarily due to the $45.2 million, or 17.8%, decrease in products sales revenue. Further contributing to our lower gross profit, as well as our lower gross profit margin, on products sales for the nine months ended September 30, 2024 is a $4.3 million increase in the provision recorded for inventory obsolescence during the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023.
Services gross profit and gross profit margin
For the nine months ended September 30, 2024, gross profit from services sales decreased $1.4 million, or 2.7%, as compared to the nine months ended September 30, 2023. The decrease in services gross profit for the nine months ended September 30, 2024, despite the $1.1 million increase in our reported services revenue for the period, was primarily driven by $4.5 million of incremental variable consideration revenue recognized by the Company's Healthcare Solutions segment during the nine months ended September 30, 2023 upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement were probable of being earned. As there were no direct costs (e.g., costs of goods sold) associated with this incremental collaboration and licensing revenue, the entire $4.5 million contributed to an increase in reported gross profit and gross profit margin realized on services revenue for the nine months ended September 30, 2023. The Company did not recognize a similar catch-up adjustment to services revenue during the nine months ended September 30, 2024.
Consolidated selling, general and administrative expense
SG&A expense for the nine months ended September 30, 2024 increased $16.1 million, or 10.7%, to $166.8 million, as compared to $150.6 million for the nine months ended September 30, 2023. The primary drivers of the $16.1 million increase in SG&A expense reported for the nine months ended September 30, 2024 are as follows:
| Increase / (Decrease) | |
|---|---|
| Volumetric earnout | $17,280 |
| Audit, legal and third-party consulting costs | 6,379 |
| Amortization expense | 2,821 |
| Accrued contingency expense | 1,750 |
| Compensation and benefits | (9,007) |
| Other | (3,074) |
| Total change | $16,149 |
Volumetric earnout
SG&A expense increased $17.3 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023, as the Company recognized the reversal of $17.3 million of Volumetric earnout expense during the nine months ended September 30, 2023, as compared to recognizing no Volumetric earnout expense during the nine months ended September 30, 2024. Prior to the quarter ended September 30, 2023, the Company had been accruing for a $65 million earnout payment (compensation expense) because the Company had concluded that a non-financial, scientific milestone included in the acquisition agreement related to the Company's December 2021 acquisition of Volumetric was probable of achievement. However, during the three months ended September 30, 2023, the Company concluded that this non-financial, scientific milestone was no longer probable of achievement given a reduction in the budgeted funding for the related R&D efforts. Accordingly, the Company reversed all previously recognized earnout expense related to the non-financial, scientific milestone during the three months ended September 30, 2023, and has recognized no earnout expense related to this non-financial, scientific milestone in reporting periods occurring thereafter. Furthermore, as a result of events that have occurred during the nine months ended September 30, 2024, the Company has notified the sellers of Volumetric that they are no longer eligible to earn any of the milestone-based earnout payments contemplated in the Volumetric acquisition agreement. Refer to the discussions in Note 12 and Note 17 to the Financial Statements, for additional details regarding the Company's cancellations of the Volumetric sellers' rights to future earnout payments, as well as actions taken in response to these cancellations.
Audit, legal and third-party consulting costs
Audit, legal and third-party consulting costs increased $6.4 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023, primarily due to significant increases in the cost to complete our fiscal year 2023 audit, including costs paid to our former independent registered public accounting firm and third-party accounting and finance consulting support costs. The increases in audit and third-party consulting costs were partially offset by lower acquisition-related legal costs as compared to the nine months ended September 30, 2023 when the Company was pursuing a large acquisition.
Amortization expense
Amortization expense increased by $2.8 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. This increase in amortization expense was primarily due to a reduction in the estimated remaining useful lives of certain intangible assets, resulting in the recognition of higher amortization expense during the three months ended September 30, 2024. Partially offsetting the impact of the reduced useful lives for certain intangible assets is lower amortization expense resulting from impairment charges that reduced the carrying values of intangible assets included in both the Oqton MOS asset group (refer to Note 5) and the dp polar asset group to $0 during the three months ended September 30, 2023 and December 31, 2023, respectively. Refer to the discussion of "Other Strategic Business Decisions and Cost Saving Initiatives" within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding the Company's recent actions taken with respect Oqton.
Accrued contingency expense
Accrued contingency expense increased due to the accrual of $1.8 million relating to a proposed settlement with the former shareholders and key employees of Volumetric. Refer to Note 17 to the Financial Statements for additional details regarding the ongoing mediation with the former shareholders and key employees of Volumetric.
Compensation and benefits
Compensation and benefits expense decreased by $9.0 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. This decrease was primarily driven by a $6.4 million decrease in stock-based compensation expense (excluding the impact of the reversal of the portion of the Volumetric earnout expense discussed above that was subject to settlement in shares of Common Stock) and a $3.4 million decrease in severance expense, partially offset by a $1.6 million increase in bonus expense. The decrease in stock-based compensation expense for the nine months ended September 30, 2024 is primarily due to (1) the reversal of previously recognized stock compensation expense due to forfeitures of a significant volume of unvested awards that were held by employees terminated under the Company's 2023 Restructuring Plan during the nine months ended September 30, 2024 and (2) the delayed grant of fiscal year 2024 annual share-based payment awards under the Company's 2015 Incentive Plan until September and October of 2024, as compared to fiscal year 2023 annual share-based payment award grants occurring in April of 2023. The decrease in stock-based compensation expense related to award forfeitures and delayed grants of new stock-based compensation awards during fiscal year 2024 was partially offset by higher share-based bonus expense and higher share-based dp polar earnout expense recognized during the nine months ended September 30, 2024.
Cash bonus expense for the nine months ended September 30, 2024 and September 30, 2023 reflects the amount of cash bonus compensation required to be recognized to appropriately report the Company's bonus liability as of each respective balance sheet date. The liability reported as of each balance sheet date is based upon management's estimate of annualized bonus expense, after consideration of the Company's performance relative to annual performance targets established under the bonus plan. Cash bonus expense recognized for the nine months ended September 30, 2024 increased, as compared to the nine months ended September 30, 2023, as the Company continued to accrue incremental bonus expense throughout the nine month period ended September 30, 2024, based upon management's estimate of the fiscal year 2024 annual bonus expense; whereas, the Company reversed substantially all of the previously accrued fiscal year 2023 bonus expense during the three months ended September 30, 2023.
The decrease in severance expense recognized for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023, is due to the recognition of significantly higher severance and termination benefit charges that were recorded to SG&A expense during the prior year period in connection with our 2023 Restructuring Plan. Under our 2023 Restructuring Plan, employee severance and termination benefit costs generally have been recognized when probable and estimable because they are typically being determined consistent with the Company’s past practices or statutory law. Furthermore, the classification of these severance and termination benefit costs in our statement of operations is based upon the classification of the ordinary compensation expense attributable to the impacted employees.
Consolidated research and development expense
R&D expense for the nine months ended September 30, 2024 decreased $0.7 million, or 1.0%, to $66.3 million, as compared to $67.0 million for the nine months ended September 30, 2023. R&D expense decreased during the nine months ended September 30, 2024 due to cost savings realized under the Company's 2023 Restructuring Plan, as well as a decrease in costs due to the sale of Oqton Dental. Refer to the discussion in the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A for additional details regarding these activities.
The decrease in R&D expense due to cost savings realized under the Company's 2023 Restructuring Plan and the sale of Oqton Dental was substantially offset by increases to R&D expense due to (1) the year-over-year ramp up of activities performed by our wholly-owned bio-tech subsidiary, Systemic Bio, which is focused on the design and manufacture of 3D-printed vascularized “organs-on-chips” for use in drug development by pharmaceutical industry customers and (2) R&D expense that continued to be incurred related to the Company's discontinued kidney and liver regenerative medicine R&D program after the Company was no longer being reimbursed for such costs by its strategic partner, but prior to winding down the resources that had been committed to the kidney and liver program. Refer to the discussion in the "Investing in Regenerative Medicine" section of this MD&A for additional details regarding Systemic Bio and the discontinuance of the kidney and liver regenerative medicine R&D program. Further, for the nine months ended September 30, 2024, R&D cost savings attributable to the 2023 Restructuring Plan and the sale of Oqton Dental were partially offset by higher R&D costs incurred related to Wematter. Wematter was acquired by the Company on July 1, 2023 and, accordingly, was not included in the Company's reported results for the full nine months ended September 30, 2023.
Asset impairment charges
During the nine months ended September 30, 2024 and 2023, we recorded asset impairment charges of $143,733 and $13,597, respectively. The following table summarizes the nature of the assets for which impairment charges were recorded during the nine months ended September 30, 2024 and 2023:
(in thousands)
| Nine Months Ended September 30, 2024 | 2023 | |
|---|---|---|
| Goodwill | $101,445 | $— |
| Intangible assets | 31,198 | 13,597 |
| Property and equipment | 5,911 | — |
| Right-of-use assets | 5,179 | — |
| Total | $143,733 | $13,597 |
Impairments during the nine months ended September 30, 2024
As a result of the significant decline in the trading price of our Common Stock and our market capitalization during the three months ended September 30, 2024, as well as reduced long-term cash flow forecasts prepared in connection with the Company's recently commenced long-range planning process, the Company concluded that the performance of an interim period goodwill impairment test was required as of September 30, 2024. For purposes of this goodwill impairment test, all of our goodwill was allocated to our Healthcare Solutions reportable segment, which also represents the reporting unit to which the goodwill is assigned for testing purposes. The performance of the interim period goodwill impairment test required the Company to compare the carrying value of the Healthcare Solutions reporting unit to its fair value estimated as of September 30, 2024. The carrying value of this reporting unit was estimated to exceed its fair value by $101.4 million, resulting in the recognition of a goodwill impairment charge equal to such amount for the nine months ended September 30, 2024. Refer to Note 6 for additional details regarding the goodwill impairment charge.
During the three months ended September 30, 2024, the Company concluded that the reduced long-term cash flow forecasts prepared in connection with the Company's recently commenced long-range planning process, combined with the Company's reported losses and negative cash flows for both current and historical reporting periods, were indicators that the primary asset group underlying the Company's core operations should be tested for recoverability. As discussed in Note 1, Note 5 and Note 8 the Company determined that the carrying value of its primary asset group exceeded its fair value. This resulted in the recognition of impairment charges of $31.2 million, $5.9 million and $5.2 million related to intangible assets, property and equipment, and right-of-use assets, respectively during the nine months ended September 30, 2024.
Impairments during the nine months ended September 30, 2023
During the quarter ended September 30, 2023, the Company concluded that it was more likely than not that it would sell or otherwise dispose of Oqton MOS, a business which the Company had acquired in 2021. Based upon the Company's expectation to sell or otherwise dispose of Oqton MOS, the Company assessed the carrying value of Oqton MOS's long-lived assets, a discrete asset group consisting primarily of product technology and trade name intangible assets initially recorded when Oqton MOS was acquired, for both recoverability and impairment. The Company's assessment resulted in the recognition of impairment charges totaling $13.6 million related to the acquired technology and trade names included in the Oqton MOS asset group during the nine months ended September 30, 2023. Refer to Note 5 to the Financial Statements for additional details.
Consolidated operating loss
Our operating loss for the nine months ended September 30, 2024 was $247.0 million, as compared to a $78.7 million operating loss for the nine months ended September 30, 2023. Our reported operating loss for the nine months ended September 30, 2024 increased due to (1) the significant increase in the asset impairment charges recognized; (2) the significant increase in SG&A costs, which includes the impact of reversing the Volumetric earnout expense liability during the nine months ended September 30, 2023, as there was not a comparable significant reversal of an expense or liability during the nine months ended September 30, 2024; and (3) the decrease in our gross profit realized for the nine months ended September 30, 2024 due to lower reported revenue and lower realized gross profit margins. Refer to the revenue, gross profit and cost discussions above for additional details.
Non-Operating Income (Loss) for the Three and Nine Months Ended September 30, 2024 compared to the Three and Nine Months Ended September 30, 2023
Other (loss) income, net
The following table sets forth the components of non-operating income for the three and nine months ended September 30, 2024 and 2023.
(in thousands)
| Non-operating income (expense): | Three Months Ended September 30, 2024 | September 30, 2023 | Nine Months Ended September 30, 2024 | September 30, 2023 |
|---|---|---|---|---|
| Foreign exchange loss, net | $(1,960) | $(2,202) | $(774) | $(3,847) |
| Interest income | 1,550 | 5,841 | 5,800 | 15,730 |
| Interest expense | (606) | (932) | (1,944) | (2,612) |
| Other (loss) income, net | (51) | (105) | 21,719 | 420 |
| Total non-operating (loss) income | $(1,067) | $2,602 | $24,801 | $9,691 |
Interest income
For the three and nine months ended September 30, 2024, interest income decreased as compared to the three and nine months ended September 30, 2023 due to the Company's lower cash and cash equivalent balances during the three and nine months ended September 30, 2024.
Interest expense
For the three and nine months ended September 30, 2024, interest expense decreased as compared to the three and nine months ended September 30, 2023 due to the Company's repurchases of debt in December of 2023 and March of 2024. In connection with each of these repurchases of debt, the Company wrote off a portion of the unamortized debt issuance costs, which resulted in lower amortization of debt issuance costs and, accordingly, interest expense for the three and nine months ended September 30, 2024.
Other income, net
For the three months ended September 30, 2024, other income, net was relatively flat as compared to the three months ended September 30, 2023. For the nine months ended September 30, 2024, other income, net increased, as compared to the nine months ended September 30, 2023, primarily due to the recognition of a $21.5 million gain on the extinguishment of debt during the nine months ended September 30, 2024.
Net loss
The following table sets forth the net loss attributable to 3D Systems Corporation for the three and nine months ended September 30, 2024 and 2023.
(in thousands, except per share amounts)
| Three Months Ended September 30, 2024 | September 30, 2023 | Nine Months Ended September 30, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Loss before income taxes | $(181,825) | $(10,982) | $(222,231) | $(69.018) |
| Benefit (provision) for income taxes | 4,343 | (174) | 2,496 | (404) |
| Loss on equity method investment, net of income taxes | (1,254) | (605) | (2,403) | (747) |
| Net loss before redeemable non-controlling interest | (178,736) | (11,761) | (222,138) | (70,169) |
| Less: net loss attributable to redeemable non-controlling interest | (109) | (57) | (252) | (149) |
| Net loss attributable to 3D Systems Corporation | $(178,627) | $(11,704) | $(221,886) | $(70,020) |
| Net loss per common share: | ||||
| Basic | $(1.35) | $(0.09) | $(1.69) | $(0.54) |
| Diluted | $(1.35) | $(0.09) | $(1.69) | $(0.54) |
Provision for income taxes
We reported an income tax benefit of $4.3 million for the three months ended September 30, 2024, as compared to income tax expense of $0.2 million for the three months ended September 30, 2023. Tax amounts reported for the three months ended September 30, 2024 and September 30, 2023 differed significantly from amounts that would be reported based upon our U.S. and foreign jurisdictions' statutory tax rates due to the Company's reported losses and the recognition of full valuation allowances against the resulting deferred tax assets in most jurisdictions where the losses have occurred.
We reported an income tax benefit of $2.5 million for the nine months ended September 30, 2024, as compared to income tax expense of $0.4 million for the nine months ended September 30, 2023. Tax amounts reported for the nine months ended September 30, 2024 and September 30, 2023 differed significantly from amounts that would be reported based upon our U.S. and foreign jurisdictions' statutory tax rates due to the Company's reported losses and the recognition of full valuation allowances against the resulting deferred tax assets in most jurisdictions where the losses have occurred.
Loss on equity method investment, net of income taxes
We hold a 49% investment ownership interest in a joint venture, NAMI, that we account for under the equity method of accounting. (Refer to Note 7 to the Financial Statements for further details.) Under the equity method of accounting, we recognize our proportionate share of NAMI's reported net income or reported net losses ("equity method income" or "equity method losses", respectively) on a one quarter lag, and we defer the recognition of 49% of intra-entity profits related to products that the Company has sold to NAMI that continue to remain on NAMI's balance sheet. The increases in the reported losses on equity method of investment for both the three and nine months ended September 30, 2024, as compared to the three and nine months ended September 30, 2023, primarily reflect increased losses reported by NAMI and our application of the equity method of accounting to this investment. In addition, our reported loss on equity method investment for the nine months ended September 30, 2024 reflects the recognition of equity method losses for a nine-month period; whereas, for the nine months ended September 30, 2023, we did not commence the recognition of equity method losses until April 1, 2023 due to the timing of our investment in this joint venture and our recognition of equity method losses on a one quarter lag.
Net loss attributable to 3D Systems Corporation
Our reported net loss attributable to 3D Systems Corporation increased $166.9 million for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. Our loss from operations increased by $167.2 million for the three months ended September 30, 2024. In addition, the Company recognized a $3.7 million decrease in our non-operating income and a $0.6 million increase in our loss on equity method investment for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The increases in our loss from operations and loss on equity investment, along with the decrease in non-operating income, were partially offset by the impact of recognizing a tax benefit of $4.3 million for the three months ended September 30, 2024, as compared to tax expense of $0.2 million for the three months ended September 30, 2023. Refer to the discussions above for additional details regarding the factors that contributed to our higher reported loss from operations, lower reported non-operating income, higher loss on equity method investment, and tax benefit for the three months ended September 30, 2024.
Our reported net loss attributable to 3D Systems Corporation increased $151.9 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. This increase in our reported loss was primarily driven by a $168.3 million increase in our loss from operations for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. Additionally, this increase in reported loss was driven by an increase in our loss on equity method investment of $1.7 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. The increases in our reported loss from operations and loss on equity method investment were partially offset by (1) a $15.1 million increase in our non-operating income for the nine months ended September 30, 2024, which is mainly attributable to the $21.5 million gain recognized on debt extinguishment during the period, and (2) and the recognition of a $2.5 million tax benefit for the nine months ended September 30, 2024, as compared to a $0.4 million tax expense for the nine months ended September 30, 2023. Refer to the discussions above for additional details regarding the factors that contributed to our higher reported loss from operations, higher loss on equity method investment, higher reported non-operating income, and tax benefit for the nine months ended September 30, 2024.
Non-GAAP Earnings
Our Adjusted EBITDA decreased from positive $4.7 million for the three months ended September 30, 2023 to negative $14.3 million for the three months ended September 30, 2024. This decrease in our Adjusted EBITDA is the result of a $13.6 million decrease in our reported gross profit for the three months ended September 30, 2024 due to lower reported revenue and lower gross profit margins, accompanied by an increase in the core operating costs included in the determination of Adjusted EBITDA. The most significant contributors to the increase in our core operating costs were higher external audit and consulting fees and certain legal expenses. Our measurement of Adjusted EBITDA excludes certain non-cash expenses, certain operating expenses that we do not believe to be reflective of our core operations, and non-operating expenses. Refer to the reconciliation of our reported Net loss attributable to 3D Systems to Adjusted EBITDA below for details regarding the amounts incurred related to (1) non-cash and non-core operating expenses and (2) non-operating expenses that have been excluded from the measurement of Adjusted EBITDA for the three months ended September 30, 2024 and 2023.
Our Adjusted EBITDA decreased from negative $12.3 million for the nine months ended September 30, 2023 to negative $47.3 million for the nine months ended September 30, 2024. This decrease in our Adjusted EBITDA is the result of a $22.7 million decrease in our reported gross profit for the nine months ended September 30, 2024 due to lower reported revenue and lower gross profit margins, accompanied by an increase in the core operating costs included in the determination of Adjusted EBITDA. The most significant contributors to the increase in our core operating costs were higher external audit and consulting fees, higher regenerative medicine R&D costs related to the ramp up of activities performed by Systemic Bio and the discontinued kidney and liver R&D programs (as described above), and certain legal expenses. Partially offsetting those increases in our core operating costs were lower R&D costs resulting from the execution of our 2023 Restructuring Plan and the sale of Oqton Dental. Our measurement of Adjusted EBITDA excludes certain non-cash expenses, certain operating expenses that we do not believe to be reflective of our core operations, and non-operating expenses. Refer to the reconciliation of our reported Net loss attributable to 3D Systems Corporation to Adjusted EBITDA below for details regarding the amounts incurred related to the (1) non-cash and non-core operating expenses and (2) non-operating expenses that have been excluded from the measurement of Adjusted EBITDA for the nine months ended September 30, 2024 and 2023.
Reconciliation of Non-GAAP Measures
The table that follows provides a reconciliation of the Company's reported Net loss attributable to 3D Systems Corporation to Adjusted EBITDA. Refer to the discussion of "How We Assess the Performance of Our Business" for additional information regarding Adjusted EBITDA, and why management believes this measure provides useful information regarding the Company's results of operations.
(in thousands)
| Three Months Ended September 30, 2024 | September 30, 2023 | Nine Months Ended September 30, 2024 | September 30, 2023 | |
|---|---|---|---|---|
| Net loss attributable to 3D Systems Corporation | $(178,627) | $(11,704) | $(221,886) | $(70,020) |
| Interest (income) expense, net | (944) | (4,909) | (3,856) | (13,118) |
| Provision (benefit) for income taxes | (4,343) | 174 | (2,496) | 404 |
| Depreciation expense | 4,644 | 5,084 | 14,514 | 15,690 |
| Amortization expense | 8,357 | 3,179 | 13,260 | 9,676 |
| Stock-based compensation expense | 5,796 | (3,142) | 17,370 | 15,140 |
| Acquisition and divestiture-related expense | 577 | (4,055) | 815 | 134 |
| Legal and other related costs | 2,619 | 2,145 | 9,200 | 4,880 |
| Restructuring expense | 690 | 1,504 | 828 | 6,712 |
| Redeemable non controlling interest | (109) | (57) | (252) | (149) |
| Loss on equity method investments, net of tax | 1,254 | 605 | 2,403 | 747 |
| Gain on repurchase of debt | — | — | (21,518) | — |
| Asset impairment charges | 143,733 | 13,595 | 143,733 | 14,211 |
| Other non-operating (income) expense, net | 2,011 | 2,307 | 573 | 3,427 |
| Adjusted EBITDA | $(14,342) | $4,726 | $(47,312) | $(12,266) |
Segment Financial Results for the Three Months Ended September 30, 2024 and September 30, 2023
The Company has two reportable segments: Healthcare Solutions and Industrial Solutions. Our reportable segments are based upon the industry verticals that they serve and reflect how we report our financial results to the Company's chief operating decision maker ("CODM").
Our CODM evaluates the performance of our reportable segments based upon Segment Revenue and Segment Adjusted EBITDA. Segment Adjusted EBITDA excludes (1) expenses related to corporate functions such as human resources, finance, and legal – inclusive of salaries, benefits, and other related costs – and (2) the non-cash and non-core operating expenses and non-operating income and expenses that we exclude from our calculation of consolidated Adjusted EBITDA (as reflected in our reconciliation of our consolidated Net loss attributable to 3D Systems Corporation to Adjusted EBITDA above). Unallocated corporate expenses are not discussed separately because any variances that have had a significant impact on our operating results for the three months and nine months ended September 30, 2024, as compared to the three and nine months ended September 30, 2023, are addressed in the discussions of our “Consolidated Operating Results for the Three Months Ended September 30, 2024 Compared to the Three Months Ended September 30, 2023” and our “Consolidated Operating Results for the Nine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023”, respectively, as included above.
The following table presents revenue and Adjusted EBITDA for our Healthcare Solutions segment and our Industrial Solutions segment for the three months ended September 30, 2024 and 2023:
(in thousands)
| Segment Revenue Three Months Ended September 30, 2024 | September 30, 2023 | Change | Segment Adjusted EBITDA Three Months Ended September 30, 2024 | September 30, 2023 | Change | |
|---|---|---|---|---|---|---|
| Healthcare Solutions | $55,056 | $52,429 | $2,627 | $12,032 | $13,869 | $(1,837) |
| Industrial Solutions | 57,884 | 71,362 | (13,478) | (2,617) | 7,662 | (10,279) |
| Total Segment Results | $112,940 | $123,791 | $(10,851) | $9,415 | $21,531 | $(12,116) |
Healthcare Solutions
Revenue
For the three months ended September 30, 2024, Healthcare Solutions revenue increased $2.6 million, or 5.0%, as compared to the three months ended September 30, 2023. This increase in segment revenue was driven by a $4.5 million increase in products revenue, partially offset by a $1.9 million decrease in services revenue.
Products Revenue
For the three months ended September 30, 2024, the $4.5 million increase in Healthcare Solutions products revenue includes a $7.7 million increase in materials revenue, partially offset by a $3.1 million decrease in printers and products revenue. The $7.7 million increase in materials revenue includes a $13.4 million increase in materials revenue due to an increase in sales volume, partially offset by a $5.9 million decrease in materials revenue due to unfavorable price/mix. The increase in material sales volume for the three months ended September 30, 2024 is primarily attributable to a significant increase in the volume of materials sold to our key customer in the dental industry, to which materials sales returned to normalized levels for the three months ended September 30, 2024. During the three months ended September 30, 2023, we experienced a lower volume of materials sales to our key customer in the dental industry due to the customer's higher inventory on hand during the period.
The significant increase in the volume of materials sales to our key customer in the dental industry is also the primary driver of the $5.9 million decrease in materials revenue due to unfavorable mix, due to lower pricing of the materials sales as compared to the three months ended September 30, 2023. During the quarter ended June 30, 2024, the Company executed a new materials sales contract with this key dental industry customer, under which materials sales to this key dental industry customer are expected to continue to exceed prior year levels for the remainder of the current year, but the pricing of the materials sold to this key dental customer is expected to remain lower than prior year's pricing for the remainder of the current year, including due to volume pricing discounts. Accordingly, price/mix is expected to continue to have an unfavorable impact on our Health Solutions materials and total revenue for the remainder of the current year.
The $3.1 million decrease in printers and products revenue was primarily driven by a decrease in revenue attributable to our regenerative medicine collaborative arrangement with a key strategic partner. Lower revenue attributable to the collaborative arrangement with this key strategic partner is due to the loss of funding for kidney and liver R&D efforts under the contract with this key strategic partner, as well as a decrease in funded lung R&D activity performed under the arrangement during the three months ended September 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine," within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A, for details regarding the changes to this regenerative medicine program during the current fiscal year.
Services Revenue
The primary driver of the $1.9 million decrease in services revenue for the three months ended September 30, 2024 was $4.5 million of nonrecurring incremental variable consideration revenue recognized by the Healthcare Solutions segment during the three months ended September 30, 2023 upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement were probable of being earned. The Company did not recognize a similar catch-up adjustment to services revenue during the three months ended September 30, 2024. Partially offsetting the $4.5 million decrease in services revenue due to the incremental milestone revenue recognized in the prior year was higher revenue attributable to personalized healthcare services and higher maintenance revenue related to the installed printer base at our key dental industry customer for the three months ended September 30, 2024.
For the three months ended September 30, 2024, Adjusted EBITDA for our Healthcare Solutions segment decreased by $1.8 million, or 13.2%, as compared to the three months ended September 30, 2023. Adjusted EBITDA decreased $1.8 million despite a $2.6 million increase in revenue, primarily due to the $4.5 million of nonrecurring incremental variable consideration revenue recognized by the Healthcare Solutions segment during the three months ended September 30, 2023 (as discussed above). As there were no direct costs (e.g., costs of goods sold) associated with this incremental variable consideration revenue, the entire $4.5 million contributed to an increase in segment Adjusted EBITDA reported for the three months ended September 30, 2023.
Industrial Solutions
Revenue
For the three months ended September 30, 2024, Industrial Solutions revenue decreased $13.5 million, or 18.9%, as compared to the three months ended September 30, 2023. This decrease in segment revenue was driven by a $12.0 million decrease in products revenue and a $1.5 million decrease in services revenue.
Products Revenue
The $12.0 million decrease in products revenue for the three months ended September 30, 2024 reflects an $8.5 million decrease in printer revenue and a $3.5 million decrease in materials revenue. Lower sales volumes contributed to $9.0 million of the decrease in printer and materials revenue, as sales of each were impacted by general economic conditions. In addition, lower materials pricing contributed to the $3.5 million decrease in materials revenue.
Services Revenue
The primary drivers of the $1.5 million decrease in services revenue for the three months ended September 30, 2024 are a lower installed printer base, reflective of the lower printer sales volume experienced by the segment, and the impacts of general economic conditions.
For the three months ended September 30, 2024, Adjusted EBITDA for our Industrial Solutions segment decreased by $10.3 million, or 134.2%, as compared to the three months ended September 30, 2023. The primary driver of the decrease in Adjusted EBITDA was the $13.5 million decrease in segment revenue and the corresponding $11.2 million decrease in gross profit. Partially offsetting the lower segment revenue and segment gross profit was a $0.9 million decrease in segment R&D expense, which was primarily attributable to cost savings realized as a result of the Company's 2023 Restructuring Plan and the sale of Oqton Dental.
Segment Financial Results for the Nine Months Ended September 30, 2024 and 2023
The following table presents revenue and Adjusted EBITDA for our Healthcare Solutions segment and our Industrial Solutions segment for the nine months ended September 30, 2024 and 2023:
(in thousands)
| Segment Revenue Nine Months Ended September 30, 2024 | September 30, 2023 | Change | Segment Adjusted EBITDA Nine Months Ended September 30, 2024 | September 30, 2023 | Change | |
|---|---|---|---|---|---|---|
| Healthcare Solutions | $149,369 | $162,028 | $(12,659) | $24,524 | $30,328 | $(5,804) |
| Industrial Solutions | 179,728 | 211,193 | (31,465) | 2,823 | 16,828 | (14,005) |
| Total Segment Results | $329,097 | $373,221 | $(44,124) | $27,347 | $47,156 | $(19,809) |
Healthcare Solutions
Revenue
For the nine months ended September 30, 2024, Healthcare Solutions revenue decreased $12.7 million, or 7.8%, as compared to the nine months ended September 30, 2023. This decrease in segment revenue was driven by a $12.1 million decrease in products revenue and a $0.5 million decrease in services revenue.
Products Revenue
For the nine months ended September 30, 2024, the $12.1 million decrease in Healthcare Solutions products revenue was primarily driven by a $14.9 million decrease in revenue due to the unfavorable impact of price/mix of product sales during the period, partially offset by a $2.6 million increase in revenue attributable to higher products sales volume. The $14.9 million decrease in revenue attributable to changes in the price/mix of products sales is primarily due to increased sales of materials to our key customer in the dental industry (see further discussion below) at lower pricing during the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. During the quarter ended June 30, 2024, the Company executed a new materials sales contract with this key dental industry customer, under which materials sales to this key dental industry customer are expected to continue to exceed prior year levels for the remainder of the current year, but the pricing of the materials sold to this key dental customer is expected to remain lower than prior year's pricing for the remainder of the current year, including due to volume pricing discounts. Accordingly, price/mix is expected to continue to have an unfavorable impact on our Health Solutions materials and total revenue for the remainder of the current year.
The $2.6 million increase in revenue attributable to higher sales volume reflects a $33.4 million increase in materials revenue due to higher sales volume, partially offset by a $30.8 million decrease in printer and products revenue due to lower sales volume. For the nine months ended September 30, 2024, a significant increase in materials sales to our key customer in the dental industry was the largest contributor to the higher materials sales volume for the period. Sales of materials to this key customer returned to normalized levels; whereas, we experienced lower material sales to this key customer during the nine months ended September 30, 2023 due to the customer's higher inventory on hand during the prior year period. Partially offsetting the impact of the increase in materials sales to this key customer in the dental industry was a decrease in the volume of printers sold to this customer during the nine months ended September 30, 2024. We expect limited printer sales to this key customer in the dental industry for the remainder of 2024, as this customer significantly expanded its printer capacity between 2022 and the quarter ended September 30, 2023. Our Healthcare Solutions segment also experienced a decrease in the volume of printer sales in other areas of the business due to the general impact of macroeconomic conditions on printer sales given the capital expenditure nature of such customer purchases.
In addition, the $30.8 million decrease in printer and products revenue due to lower sales volume includes a $6.4 million decrease in revenue attributable to our regenerative medicine collaborative arrangement with a key strategic partner. Lower revenue attributable to this collaborative arrangement with our strategic partner is due to the loss of funding for kidney and liver R&D efforts under the contract, as well as a decrease in funded lung R&D activity performed under the collaborative arrangement during the nine months ended September 30, 2024. Refer to the discussion of "Investing in Regenerative Medicine", within the "Recent Developments and Updates Regarding Strategic Initiatives" section of this MD&A, for details regarding the changes to this regenerative medicine program during the current fiscal year.
Services Revenue
For the nine months ended September 30, 2024, services revenue for the Healthcare Solutions segment decreased $0.5 million. Contributing to this decrease in services revenue was (1) a $3.0 million decrease in parts manufacturing revenue and (2) $4.5 million of nonrecurring incremental variable consideration revenue recognized by the Healthcare Solutions segment during the nine months ended September 30, 2023 upon concluding that additional milestone-based payments included in a collaboration and licensing revenue agreement were probable of being earned; whereas, the Company did not recognize a similar catch-up adjustment to services revenue during the nine months ended September 30, 2024. Partially offsetting the $3.0 million decrease in parts manufacturing revenue and the $4.5 million decrease in services revenue due to the incremental milestone revenue recognized in the prior year was $4.8 million of higher revenue attributable to personalized healthcare services and higher maintenance revenue related to the installed printer base at our key dental industry customer.
For the nine months ended September 30, 2024, Adjusted EBITDA for our Healthcare Solutions segment decreased $5.8 million, or 19.1%, as compared to the nine months ended September 30, 2023. This decrease in Adjusted EBITDA was partially driven by the $12.7 million decrease in segment revenue, which resulted in a $3.8 million decrease in gross profit. Contributing to the decrease in segment revenue and gross margin and, accordingly, segment Adjusted EBITDA is the $4.5 million of nonrecurring variable consideration revenue recognized by the Healthcare Solutions segment during the nine months ended September 30, 2023 (as discussed above), as there were no direct costs (e.g., costs of goods sold) associated with this incremental variable consideration revenue. Further contributing to the decrease in segment Adjusted EBITDA was $4.3 million of higher regenerative medicine R&D costs related to the ramp up of activities performed by Systemic Bio and the discontinued kidney and liver R&D programs, partially offset by $1.7 million in R&D and SG&A cost savings attributable to the Company's 2023 Restructuring Plan.
Industrial Solutions
Revenue
For the nine months ended September 30, 2024, Industrial Solutions revenue decreased $31.5 million, or 14.9%, as compared to the nine months ended September 30, 2023. This decrease in segment revenue was driven by a $33.1 million decrease in products revenue, partially offset by a $1.6 million increase in services revenue.
Products Revenue
For the nine months ended September 30, 2024, the primary driver of the $33.1 million decrease in products revenue was a $17.0 million decrease in printers revenue due to lower sales volume and a $16.8 million decrease in materials revenue due to lower sales volume. Lower printers and materials sales volume and revenue for the nine months ended September 30, 2024 was primarily driven by the general impact of macroeconomic conditions, as well as certain large discrete printer and materials revenue transactions that occurred during the nine months ended September 30, 2023, for which there have not been comparable large discrete printer and materials revenue transactions that have occurred during the nine months ended September 30, 2024.
Services Revenue
The $1.6 million increase in services revenue for the nine months ended September 30, 2024 primarily relates to increased parts manufacturing revenue, partially offset by lower hardware services revenue.
For the nine months ended September 30, 2024, Adjusted EBITDA for our Industrial Solutions segment decreased $14.0 million, or 83.2%, as compared to the nine months ended September 30, 2023. The primary driver of the decrease in Adjusted EBITDA was the $31.5 million decrease in segment revenue and a corresponding $18.7 million decrease in gross profit. Partially offsetting lower segment revenue and segment gross profit was a $6.6 million decrease in segment R&D and SG&A cost savings resulting from the Company's 2023 Restructuring Plan and the sale of Oqton Dental.
Liquidity and Capital Resources
The following table sets forth the Company's operating working capital at September 30, 2024 and December 31, 2023.
(Dollars in thousands)
| September 30, 2024 | December 31, 2023 | Change $% | ||
|---|---|---|---|---|
| Cash and cash equivalents | $190,005 | $331,525 | $(141,520) | (42.7)% |
| Accounts receivable, net | 99,224 | 101,497 | (2,273) | (2.2)% |
| Inventories | 134,926 | 152,188 | (17,262) | (11.3)% |
| 424,155 | 585,210 | (161,055) | (27.5)% | |
| Less: | ||||
| Current lease liabilities | 9,628 | 9,924 | (296) | (3.0)% |
| Accounts payable | 42,414 | 49,757 | (7,343) | (14.8)% |
| Accrued and other liabilities | 44,882 | 49,460 | (4,578) | (9.3)% |
| 96,924 | 109,141 | (12,217) | (11.2)% | |
| Operating working capital | $327,231 | $476,069 | $(148,838) | (31.3)% |
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. In doing so, we review and analyze our current cash on hand, the number of days our sales are outstanding, inventory turns, capital expenditure commitments and accounts payable turns. Our cash requirements, excluding acquisitions, primarily consist of funding working capital and capital expenditures. Differences between the amounts of working capital item changes in the cash flow statement and the balance sheet changes for the corresponding items are primarily the result of foreign currency translation adjustments, acquisitions and divestitures.
At September 30, 2024, cash and cash equivalents totaled $190.0 million and decreased $141.5 million since December 31, 2023. This decrease resulted primarily from cash used in operations of $37.1 million, capital expenditures of $10.8 million, and repayment on borrowings of $87.2 million.
Cash held outside the U.S. at September 30, 2024 was $64.0 million, or 33.7% of total cash and cash equivalents, compared to $65.8 million, or 19.8% of total cash and cash equivalents, at December 31, 2023. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. (e.g., via dividends) would not incur significant federal and state taxes. However, these dividends would be subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limit exposure to any one issuer depending upon credit quality. See “Cash Flow” discussion below.
Cash Flow
The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash on hand, cash equivalents, and financing activities as necessary. We expect that cash, cash equivalents, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet our anticipated cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:
(in thousands)
| Nine Months Ended September 30, 2024 | September 30, 2023 | Dollar Change | |
|---|---|---|---|
| Cash flow used in operating activities | $(37,109) | $(71,893) | $34,784 |
| Cash flow (used in) provided by investing activities | (13,152) | 130,689 | (143,841) |
| Cash flow used in financing activities | (90,747) | (5,215) | (85,532) |
Cash flow from operations
For the nine months ended September 30, 2024, cash used in operating activities was $37.1 million, and cash used in operating activities for the nine months ended September 30, 2023 was $71.9 million. The $34.8 million reduction in cash used in operating activities was due to a $66.8 million favorable impact of changes in working capital accounts for the nine months ended September 30, 2024, as compared to changes in the Company's working capital accounts for the nine months ended September 30, 2023. This $66.8 favorable impact attributable to working capital activity was partially offset by a $32.0 million increase in our net loss for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023, after adjustment for the $130.1 million increase in non-cash asset impairment charges, the $21.5 million gain on the extinguishment of debt recognized during the nine months ended September 30, 2024 and the following additional non-cash items recognized in each reporting period: depreciation, amortization, and accretion expense; stock-based compensation expense; non-cash operating lease expense; inventory obsolescence, and other non-cash losses and provisions. The $66.8 million favorable working capital impact was primarily the result of (1) the Company's efforts to reduce its inventory during the nine months ended September 30, 2024, as compared to an increase in the Company's inventory on-hand during the nine months ended September 30, 2023, (2) a reduction in accounts receivables during the nine months ended September 30, 2024, as compared to a significant increase in receivable during the nine months ended September 30, 2023, and (3) a favorable impact of cash used for short-term liabilities.
Cash flow from investing activities
For the nine months ended September 30, 2024, cash used in investing activities was $13.2 million, which was primarily due to capital expenditures of $10.8 million and an incremental investment in NAMI of $2.5 million.
For the nine months ended September 30, 2023, cash provided by investing activities was $130.7 million, which included $180.9 million of proceeds from the sales and maturities of short-term investments, partially offset by capital expenditures of $21.0 million and cash used for investments in strategically-aligned businesses totaling $29.2 million.
Cash flow from financing activities
For the nine months ended September 30, 2024, the cash flow used in financing activities was $90.7 million, primarily due to the use of $87.2 million to repay borrowings and the use of $2.5 million to pay taxes related to the net-share settlement of equity awards.
For the nine months ended September 30, 2023, the cash flow used in financing activities was $5.2 million primarily due to taxes paid related to the net-share settlement of equity awards of $4.8 million.
Material Cash Requirements
The Company's material cash requirements consist of the following contractual and other obligations:
Indebtedness
At September 30, 2024, we had $214.4 million of outstanding 0% convertible notes which mature in November of 2026 (the "Notes"). Management may consider pursuing additional long-term financing if it is appropriate in light of cash requirements for operations or strategic opportunities, which could result in higher financing costs.
Purchase Commitments
We have purchase commitments under legally enforceable agreements for goods and services with defined terms as to quantity, price and timing of delivery. The Company has certain purchase commitments under agreements with remaining terms in excess of a year, which primarily relate to printer assemblies, inventory, capital expenditures, and software licenses. As of September 30, 2024, such purchase commitments totaled $18.6 million, with approximately $11.3 million, expected to be due within the next twelve months.
Leases
The Company had operating and financing lease obligations (inclusive of interest) of $97.1 million at September 30, 2024, primarily related to real estate and equipment leases, of which approximately $4.2 million in payments are expected over the remainder of 2024.
National Additive Manufacturing Innovation ("NAMI") Joint Venture
In March 2022, Dussur and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. In February 2023, the Company became a shareholder in the joint venture and now owns 49% of its common stock. 3D Systems was committed to an initial investment of approximately $6.5 million of cash into the joint venture, all of which has been funded as of September 30, 2024. In May 2024, the Company made another investment in NAMI, as further discussed in Note 7 to the Financial Statements. Additional future investments in the joint venture are contingent upon agreement by the parties to the joint venture to invest additional capital. The future impact that participation in the joint venture will have on the Company’s financial position and cash flows is not expected to be material other than any potential cash outflow(s) that may be required to fund contingent investments.
Sources of Funding to Satisfy Material Cash Requirements
The Company believes that it has the financial resources needed to meet its anticipated cash requirements during the next twelve months. Cash requirements for periods beyond the next twelve months will depend on, among other things, the Company’s profitability and its ability to manage working capital requirements.
Other Contractual Commitments
Indemnification
In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences, when the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.
Critical Accounting Estimates
Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
There have been no changes to our critical accounting estimates described in our 2023 Form 10-K and our Form 10-Q for the quarterly period ended June 30, 2024. The following discussion supplements our Critical Accounting Estimates disclosure included in our 2023 Form 10-K for "Goodwill & other long-lived assets, including intangible assets" by providing a discussion of the key estimates and assumptions applied in connection with (1) testing goodwill and long-lived assets for impairment and (2) measuring the asset impairment charges recorded during the three and nine months ended September 30, 2024.
See Note 2 to the consolidated financial statements in our 2023 Form 10-K for a summary of our significant accounting policies.
Update Regarding Critical Accounting Estimates
As discussed in Note 6, as a result of the significant decline in the trading price of our common stock and our market capitalization during the three months ended September 30, 2024, the Company concluded that the performance of an interim period goodwill impairment test was required as of September 30, 2024. As discussed in Note 1, the Company further concluded that the significant decline in the Company's stock price during the period, reduced long-term cash flow forecasts prepared for purposes of the Company's interim period goodwill impairment test, and the Company's reported losses and negative cash flows for both current and historical reporting periods were indicators that the primary asset group underlying the Company's core operations should be tested for recoverability, which ultimately resulted in the Company testing this asset group for impairment as of September 30, 2024.
The performance of the long-lived asset recoverability test, the long-lived asset impairment test, and the goodwill impairment test as of September 30, 2024, as well as the measurement of impairment pursuant to these tests, required the Company to make significant estimates regarding the future cash flows expected to be generated by or associated with (1) the asset group that was tested for impairment, (2) the Company's Healthcare Solutions reporting unit to which all goodwill was assigned, and (3) the intangible assets and right-of-use assets included in the asset group that was tested for impairment. These estimates of future cash flows reflected forecasts of long-term revenue, profit margins, operating expenses, and capital expenditures, as applicable. Due to the extended period of time covered by the forecasts prepared for the Company's impairment testing, the estimates of future cash flows included the Company's recoverability test and impairment tests could change in the future – for example, based upon the Company's performance against its forecasts or changes in market conditions or other external factors that could impact the Company's operations.
In addition, the performance of the long-lived asset impairment test and goodwill impairment test required the Company to make judgments regarding appropriate discount rates, including risk premiums included in the determination of those discount rates; perpetual growth rates; and tax rates to be applied to the forecasted cash flows described above. Furthermore, the allocation of the impairment charge measured for the tested asset group required the Company to estimate the fair value of the plant, property, and equipment assets comprising the asset group, which estimates were made using a cost approach and required the application of significant assumptions, estimates, and judgments regarding the replacement costs, condition, and economic lives of the property, plant, and equipment. Due to the significant amount of judgment associated with these estimates and assumptions, these estimates and assumptions could change in the future.
As a result of the impairment testing performed, the Company recorded impairment charges of $101.4 million, $31.2 million, $5.9 million, and $5.2 million related to goodwill; intangible assets; plant, property, and equipment; and right-of-use assets, respectively. Refer to Note 1, Note 5, Note 6, and Note 8 for additional details regarding these impairment charges. If the Company was to conclude that significant changes are required in the future to the estimates, assumptions, or judgments that were included in the impairment tests performed as of September 30, 2024, further testing of impairment could be triggered.
Forward-Looking Statements
Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed, or implied by, such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These factors include without limitation:
- impact on our business as a result of macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions, inflation, interest rates and foreign exchange volatility;
- our ability to deliver products that meet changing technology and customer needs;
- our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
- our ability to realize anticipated benefits for future dispositions;
- impact of future write-off or write-downs of goodwill and intangible assets;
- the concentration of revenue and credit risk exposure from our largest customer;
- our ability to acquire and enforce intellectual property rights and defend such rights against third-party claims;
- our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
- failure of our information technology infrastructure or inability to protect against cyber-attack;
- our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
- our ability to generate net cash flow from operations;
- our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
- our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
- fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
- our ability to efficiently conduct business outside the U.S.;
- our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
- our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
- product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
- our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
- our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
- disruption in our management information systems for inventory management, distribution, and other key functions;
- compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
- our ability to maintain our status as a responsible contractor under federal rules and regulations;
- changes in, or interpretation of, tax rules and regulations; and
- the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2023 Form 10-K, the Form 10-Q for the quarterly period ended June 30, 2024 and this Form 10-Q.
Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.
Market risk
As filed, 343 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For a discussion of market risks at December 31, 2023, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2023 Form 10-K. During the three months ended September 30, 2024, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2023.
Controls and procedures
As filed, 1,818 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of September 30, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of September 30, 2024 due to the material weaknesses discussed in our 2023 Form 10-K.
Changes in Internal Control Over Financial Reporting
We are in the process of implementing certain changes to our internal controls to remediate the material weaknesses described in our 2023 Form 10-K. Related to these efforts was the development of a remediation plan to specifically address processes and activities intended to rectify the issues identified as part of the material weaknesses. These plans include, but are not limited to, increased training, enhanced documentation associated with existing policies, and talent enhancements designed to specifically address the identified weaknesses. Additionally, the Company completed a comprehensive project designed to improve controls specifically related to revenue accounting during the 3rd quarter. Aside from these activities, the results of which continue to be evaluated, there were no changes in the Company’s internal control over financial reporting during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Risk factors
As filed, 6,738 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the risk factors set forth below and the other information set forth in this Form 10-Q, you should carefully consider the factors discussed under Part I, Item 1A, “Risk Factors” in our 2023 Form 10-K and under Part II, Item 1A, "Risk Factors" in our Form 10-Q for the quarterly period ended June 30, 2024 ("Q2 2024 Form 10-Q"). These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by the forward-looking statements contained in this Form 10-Q. Except as disclosed below, there have been no material changes to the risk factors described in Part I, Item 1A, “Risk Factors,” of our 2023 Form 10-K and in Part II, Item 1A, "Risk Factors" in our Q2 2024 Form 10-Q.
Changes in business conditions may cause our goodwill, intangible assets, long-lived tangible assets, and/or right-of-use assets to become impaired.
Goodwill is subject to an impairment test on an annual basis and when circumstances indicate that an impairment is more likely than not. Long-lived assets – consisting of tangible assets, intangible assets, and right-of-use assets – are assessed for recoverability and tested for impairment at the asset group level, and testing is required when circumstances indicate that the carrying value of an asset group is not recoverable. Circumstances that may require goodwill to be tested more frequently than the annual impairment test, or indicate that a long-lived asset group is not recoverable, include a significant adverse change in the business climate, current-period operating or cash flow losses combined with a history of operating or cash flow losses, projections or forecasts that demonstrate continuing losses, or a decision to dispose of a business or product line. We face some uncertainty in our business environment due to a variety of challenges, including changes in customer demand and a recent decline in our market capitalization as a result of a decrease in our stock price. While we recorded an impairment charges of $143.7 million related to goodwill, intangible assets, tangible assets, and right-of-use assets during the three and nine months ended September 30, 2024, we may experience additional unforeseen circumstances that adversely affect the value of our these assets and trigger an evaluation of their carrying amounts. Future impairments of goodwill, intangible assets, long-lived tangible assets, and/or right-of-use assets could materially adversely affect our results of operations and financial condition.
As a result of the delayed filing of our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, our Form 10-Q for the quarter ended June 30, 2024, and this Form 10-Q, the Company has experienced risks and costs and expects to experience additional risks and costs in the future, including with respect to the SEC's ongoing investigation.
As a result of the circumstances giving rise to the delayed filing of our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, our Form 10-Q for the quarter ended June 30, 2024, and this Form 10-Q, the Company experienced risks and costs and expects to experience additional risks and costs in the future. The audit of the financial statements included in our 2023 Form 10-K was time-consuming, required the Company to incur additional incremental expenses and affected management’s attention and resources. Further, the measures to strengthen internal controls being implemented continue to require and will likely require in the future greater management time and Company resources to implement and monitor. Although we have now filed our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, our Form 10-Q for the quarter ended June 30, 2024, and this Form 10-Q, our failure to make these filings in a timely manner has led to further investigation and scrutiny by the SEC, which has been conducting a formal investigation of the Company since April 2022 as a follow on to the previously disclosed SEC voluntary request for documents. Although the Company is currently cooperating with the SEC, the Company cannot predict the ultimate outcome of the SEC’s investigation. Any allegations or adverse findings by the SEC could harm our reputation, negatively impact our stock price and have a material adverse effect on our business, financial condition and results of operations. Moreover, the expense and distraction to management of cooperating with and responding to the SEC could have a material adverse effect on the Company even if the investigation is ultimately closed or resolved in a manner favorable to the Company. See also the risk factor below entitled “We are no longer eligible to use a Form S-3 registration statement, which could impair our capital-raising activities.”
We are no longer eligible to use a Form S-3 registration statement, which could impair our capital-raising activities.
As a result of our failure to timely file our 2023 Form 10-K, our Form 10-Q for the quarter ended March 31, 2024, our Form 10-Q for the quarter ended June 30, 2024, and this Form 10-Q with the SEC, we are no longer eligible to use a Form S-3 registration statement. Further, as a result of the late 2023 Form 10-K filing, the late Form 10-Q filing for the quarter ended March 31, 2024, the late Form 10-Q for the quarter ended June 30, 2024, and this late Form 10-Q filing, we are also no longer a “well-known seasoned issuer,” as such term is used in the SEC’s regulations, which otherwise would allow us to, among other things, file automatically effective Form S-3 registration statements. Our eligibility to use a Form S-3 registration statement may not be restored until December 1, 2025, and then only if we have not had any other filing delinquency that would preclude Form S-3 eligibility and satisfy all other requirements for Form S-3 eligibility. During any period when we are not eligible to use Form S-3 or qualify as a “well known seasoned issuer,” our capital-raising ability may be impaired. Under these circumstances, we would be required to conduct the offering on an exempt basis, such as in accordance with Rule 144A, or file a registration statement on Form S-1. Using a Form S-1 registration statement for a public offering would likely take significantly longer than using a registration statement on Form S-3 and increase our transaction costs, and could, to the extent we are not able to conduct offerings using alternative methods, adversely impact our ability to raise capital or complete acquisitions of other companies in a timely manner.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $112.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $329.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $71.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $199.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $41.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-01-01 to 2024-09-30 | $129.7m | us-gaap:GrossProfit |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $20.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $66.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $58.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $166.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$180.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$247.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | −$4.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | −$2.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$178.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$221.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$1.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | −$1.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$1.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$1.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 132,235,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 131,621,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$37.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $10.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-09-30 | $190.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $460.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $658.3m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $138.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $438.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $211.7m | us-gaap:LongTermDebtNoncurrent |
Source: SEC EDGAR, the filing index for accession 0000910638-24-000046. Last ingested by Listed: Nov 15, 2026, 00:01 ET. Listed shows no prices and gives no investment advice.